Randomized_trial_of_doxorubicin,_bisantrene,_and_mitoxantrone_in_advanced_breast_cancer:_a_Southwest_Oncology_Group_study._Four_hundred_eleven_women_with_metastatic_breast_cancer_were_randomly_assigned_to_receive_either_60_mg/m2_doxorubicin_(130_patients),_320_mg/m2_bisantrene_(146_patients),_or_14_mg/m2_mitoxantrone_(135_patients)._The_doses_were_given_intravenously_every_3_weeks_with_a_cross-over_design_to_determine_their_relative_efficacy_and_toxicity._To_be_eligible,_patients_must_have_had_one_previous_chemotherapy_regimen,_and_patients_who_were_estrogen_receptor_positive_must_have_failed_endocrine_therapy._There_were_365_patients_assessable_for_response_and_399_assessable_for_toxic_effects._The_median_age_was_57_years;_18%_were_premenopausal_or_perimenopausal._Visceral_dominant_disease_was_present_in_66%_of_the_patients._Ninety-seven_percent_of_the_patients_had_a_disease-free_interval_from_diagnosis_to_first_recurrence_of_less_than_1_year._The_response_rate_was_28%_with_doxorubicin,_13%_with_bisantrene,_and_14%_with_mitoxantrone_(P_=_.004)._Median_time_to_treatment_failure_was_133_days_with_doxorubicin,_66_days_with_bisantrene,_and_68_days_with_mitoxantrone_(logrank_P_=_.06)._The_median_survival_was_315_days_for_doxorubicin,_290_days_for_bisantrene,_and_177_days_for_mitoxantrone_(logrank_P_=_.04),_although_survival_at_2_years_was_similar_for_all_three_agents._There_were_five_responses_in_the_66_patients_crossed_over_to_doxorubicin_and_one_response_each_for_patients_crossed_over_to_bisantrene_(39_patients)_or_mitoxantrone_(63_patients)._Toxicity_leading_to_discontinuance_of_therapy_was_more_common_with_doxorubicin,_and_discontinuance_of_therapy_was_due_primarily_to_patient's_request_or_cardiotoxicity._The_major_dose-limiting_toxic_effect_for_all_three_agents_was_leukopenia._Nausea_and_vomiting,_mucositis,_and_alopecia_were_more_severe_with_doxorubicin._Congestive_heart_failure_developed_in_nine_patients_treated_with_doxorubicin,_zero_patients_treated_with_bisantrene,_and_two_patients_treated_with_mitoxantrone._A_decrease_in_the_left_ventricular_ejection_fraction,_as_defined_by_moderate_to_severe_Alexander_grade_changes,_was_more_common_in_patients_treated_with_doxorubicin_(doxorubicin-treated_patients_=_20%,_bisantrene-treated_patients_=_5%,_and_mitoxantrone-treated_patients_=_10%)._This_study_demonstrates_that_bisantrene_and_mitoxantrone_have_only_modest_activity_in_metastatic_breast_carcinoma._The_activity_of_doxorubicin_is_greater_than_that_of_the_other_two_agents,_but_at_a_cost_of_increased_toxicity.